Phaseline

Companies › Lineage Cell Therapeutics

Lineage Cell Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Neurology; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
LCTOPC1
Oligodendrocyte progenitor cell therapy for spinal cord injury repair
–Phase 1Spinal Cord Injury CervicalAug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06841770LCTOPC1Phase 1Spinal Cord Injury CervicalNeurologyAug 2027

From the company's SEC filings

Cash and short-term investments of $51m on 2026-06-30; operating cash outflow about $31m a year; runway about 20 months at that burn, to Feb 2028

Press releases filed as 8-K in the last year:

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.